Shield Therapeutics (1JS) Stock Overview
A commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
1JS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shield Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.13 |
| 52 Week High | UK£0.14 |
| 52 Week Low | UK£0.022 |
| Beta | 1.95 |
| 1 Month Change | -4.55% |
| 3 Month Change | 76.22% |
| 1 Year Change | 447.83% |
| 3 Year Change | 80.00% |
| 5 Year Change | -80.47% |
| Change since IPO | -93.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1JS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.8% | 2.7% | 0.5% |
| 1Y | 447.8% | 17.5% | 14.8% |
Return vs Industry: 1JS exceeded the German Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: 1JS exceeded the German Market which returned 14.6% over the past year.
Price Volatility
| 1JS volatility | |
|---|---|
| 1JS Average Weekly Movement | 42.0% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1JS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1JS's weekly volatility has increased from 32% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 63 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc Fundamentals Summary
| 1JS fundamental statistics | |
|---|---|
| Market cap | €149.54m |
| Earnings (TTM) | -€18.30m |
| Revenue (TTM) | €35.76m |
Is 1JS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1JS income statement (TTM) | |
|---|---|
| Revenue | US$41.50m |
| Cost of Revenue | US$21.44m |
| Gross Profit | US$20.06m |
| Other Expenses | US$41.30m |
| Earnings | -US$21.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 48.34% |
| Net Profit Margin | -51.18% |
| Debt/Equity Ratio | -181.4% |
How did 1JS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 15:08 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shield Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |